Clinical guide to ABO-incompatible allogeneic stem cell transplantation

Area of Science:

• Hematology
• Transplantation Immunology
• Blood Banking

Background:

• Hematopoietic progenitor cell transplantation (HCT) often involves ABO-incompatible donor-recipient pairs due to independent inheritance of HLA and ABO blood groups.
• ABO incompatibility in HCT increases risks for recipients, including hemolytic reactions, delayed red blood cell (RBC) engraftment, and pure red blood cell aplasia.
• Minor RBC antigen discrepancies also require careful evaluation for safe transfusion management.

Purpose of the Study:

• To describe practical approaches for screening and managing ABO-incompatible HCT.
• To reduce preventable morbidity and mortality associated with ABO-incompatible HCT.
• To optimize patient outcomes and blood bank inventory management.

Main Methods:

• Review of clinical and laboratory evaluations for ABO-incompatible HCT.
• Analysis of strategies for managing major, minor, and bidirectional ABO differences.
• Focus on pretransplantation donor-recipient assessment and management protocols.

Main Results:

• ABO-incompatible HCT outcomes regarding survival, relapse, and graft-versus-host disease have shown inconsistent results.
• Effective management strategies are crucial for mitigating risks associated with ABO incompatibility.
• Unique approaches are needed for different types of ABO discrepancies.

Conclusions:

• Pretransplantation evaluation and management strategies are essential for ABO-incompatible HCT.
• Implementing specific protocols can improve patient outcomes and reduce complications.
• Optimized management benefits both patient care and blood bank resource allocation.